Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer

Patients with cancer display reduced humoral responses after double-dose COVID-19 vaccination, whereas their cellular response is more comparable with that in healthy individuals. Recent studies demonstrated that a third vaccination dose boosts these immune responses, both in healthy people and pati...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2023-02, Vol.29 (3), p.635-646
Hauptverfasser:	Debie, Yana, Van Audenaerde, Jonas R M, Vandamme, Timon, Croes, Lieselot, Teuwen, Laure-Anne, Verbruggen, Lise, Vanhoutte, Greetje, Marcq, Elly, Verheggen, Lisa, Le Blon, Debbie, Peeters, Bart, Goossens, Maria E, Pannus, Pieter, Ariën, Kevin K, Anguille, Sébastien, Janssens, Annelies, Prenen, Hans, Smits, Evelien L J, Vulsteke, Christof, Lion, Eva, Peeters, Marc, van Dam, Peter A
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Viral BNT162 Vaccine COVID-19 - prevention & control COVID-19 Vaccines Humans Immunity, Cellular Immunoglobulin G Neoplasms - therapy Prospective Studies SARS-CoV-2 Vaccination
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	646
container_issue	3
container_start_page	635
container_title	Clinical cancer research
container_volume	29
creator	Debie, Yana Van Audenaerde, Jonas R M Vandamme, Timon Croes, Lieselot Teuwen, Laure-Anne Verbruggen, Lise Vanhoutte, Greetje Marcq, Elly Verheggen, Lisa Le Blon, Debbie Peeters, Bart Goossens, Maria E Pannus, Pieter Ariën, Kevin K Anguille, Sébastien Janssens, Annelies Prenen, Hans Smits, Evelien L J Vulsteke, Christof Lion, Eva Peeters, Marc van Dam, Peter A
description	Patients with cancer display reduced humoral responses after double-dose COVID-19 vaccination, whereas their cellular response is more comparable with that in healthy individuals. Recent studies demonstrated that a third vaccination dose boosts these immune responses, both in healthy people and patients with cancer. Because of the availability of many different COVID-19 vaccines, many people have been boosted with a different vaccine from the one used for double-dose vaccination. Data on such alternative vaccination schedules are scarce. This prospective study compares a third dose of BNT162b2 after double-dose BNT162b2 (homologous) versus ChAdOx1 (heterologous) vaccination in patients with cancer. A total of 442 subjects (315 patients and 127 healthy) received a third dose of BNT162b2 (230 homologous vs. 212 heterologous). Vaccine-induced adverse events (AE) were captured up to 7 days after vaccination. Humoral immunity was assessed by SARS-CoV-2 anti-S1 IgG antibody levels and SARS-CoV-2 50% neutralization titers (NT50) against Wuhan and BA.1 Omicron strains. Cellular immunity was examined by analyzing CD4+ and CD8+ T-cell responses against SARS-CoV-2-specific S1 and S2 peptides. Local AEs were more common after heterologous boosting. SARS-CoV-2 anti-S1 IgG antibody levels did not differ significantly between homologous and heterologous boosted subjects [GMT 1,755.90 BAU/mL (95% CI, 1,276.95-2,414.48) vs. 1,495.82 BAU/mL (95% CI, 1,131.48-1,977.46)]. However, homologous-boosted subjects show significantly higher NT50 values against BA.1 Omicron. Subjects receiving heterologous boosting demonstrated increased spike-specific CD8+ T cells, including higher IFNγ and TNFα levels. In patients with cancer who received double-dose ChAdOx1, a third heterologous dose of BNT162b2 was able to close the gap in antibody response.
doi_str_mv	10.1158/1078-0432.CCR-22-2185
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2733202129</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2733202129</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-1dd8b2fa6894b999ef0d8e16bd7dac361fda1ad053ddbb7e4a9cf4d779e2e5a3</originalsourceid><addsrcrecordid>eNpFkdtO3DAQQK2Kqtz6Ca38yIupL3Euj0sKBQkVtKx4tSbxhHWV2IudFPik_iXZLrRPM5o5MyPNIeSL4KdC6PKb4EXJeKbkaV0vmZRMilJ_IAdC64Ipmeu9OX9n9slhSr84F5ng2Seyr3KViaxSB-TP5TSECD0Fb2mNfT_1EOnVMEwe6RLTJviEicIDOJ9GerdY3rE63DNJoRsx0tXaRUu_h4T07OdK5LKRtAt9H56cf5jrU9Mj-9u-h7Z1HkYXPH1y4_o__xtjmhKt1wt78yyo8_R2xtCPaQfW4FuMx-RjB33Cz2_xiKwuzlf1Jbu--XFVL65Zq3Q-MmFt2cgO8rLKmqqqsOO2RJE3trDQqlx0FgRYrpW1TVNgBlXbZbYoKpSoQR2Rk93aTQyPE6bRDC6182PAY5iSkYVSkkshqxnVO7SNIaWIndlEN0B8MYKbrSSzFWC2AswsyUhptpLmua9vJ6ZmQPtv6t2KegVlfo5B</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2733202129</pqid></control><display><type>article</type><title>Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>American Association for Cancer Research</source><source>Alma/SFX Local Collection</source><creator>Debie, Yana ; Van Audenaerde, Jonas R M ; Vandamme, Timon ; Croes, Lieselot ; Teuwen, Laure-Anne ; Verbruggen, Lise ; Vanhoutte, Greetje ; Marcq, Elly ; Verheggen, Lisa ; Le Blon, Debbie ; Peeters, Bart ; Goossens, Maria E ; Pannus, Pieter ; Ariën, Kevin K ; Anguille, Sébastien ; Janssens, Annelies ; Prenen, Hans ; Smits, Evelien L J ; Vulsteke, Christof ; Lion, Eva ; Peeters, Marc ; van Dam, Peter A</creator><creatorcontrib>Debie, Yana ; Van Audenaerde, Jonas R M ; Vandamme, Timon ; Croes, Lieselot ; Teuwen, Laure-Anne ; Verbruggen, Lise ; Vanhoutte, Greetje ; Marcq, Elly ; Verheggen, Lisa ; Le Blon, Debbie ; Peeters, Bart ; Goossens, Maria E ; Pannus, Pieter ; Ariën, Kevin K ; Anguille, Sébastien ; Janssens, Annelies ; Prenen, Hans ; Smits, Evelien L J ; Vulsteke, Christof ; Lion, Eva ; Peeters, Marc ; van Dam, Peter A</creatorcontrib><description>Patients with cancer display reduced humoral responses after double-dose COVID-19 vaccination, whereas their cellular response is more comparable with that in healthy individuals. Recent studies demonstrated that a third vaccination dose boosts these immune responses, both in healthy people and patients with cancer. Because of the availability of many different COVID-19 vaccines, many people have been boosted with a different vaccine from the one used for double-dose vaccination. Data on such alternative vaccination schedules are scarce. This prospective study compares a third dose of BNT162b2 after double-dose BNT162b2 (homologous) versus ChAdOx1 (heterologous) vaccination in patients with cancer. A total of 442 subjects (315 patients and 127 healthy) received a third dose of BNT162b2 (230 homologous vs. 212 heterologous). Vaccine-induced adverse events (AE) were captured up to 7 days after vaccination. Humoral immunity was assessed by SARS-CoV-2 anti-S1 IgG antibody levels and SARS-CoV-2 50% neutralization titers (NT50) against Wuhan and BA.1 Omicron strains. Cellular immunity was examined by analyzing CD4+ and CD8+ T-cell responses against SARS-CoV-2-specific S1 and S2 peptides. Local AEs were more common after heterologous boosting. SARS-CoV-2 anti-S1 IgG antibody levels did not differ significantly between homologous and heterologous boosted subjects [GMT 1,755.90 BAU/mL (95% CI, 1,276.95-2,414.48) vs. 1,495.82 BAU/mL (95% CI, 1,131.48-1,977.46)]. However, homologous-boosted subjects show significantly higher NT50 values against BA.1 Omicron. Subjects receiving heterologous boosting demonstrated increased spike-specific CD8+ T cells, including higher IFNγ and TNFα levels. In patients with cancer who received double-dose ChAdOx1, a third heterologous dose of BNT162b2 was able to close the gap in antibody response.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-22-2185</identifier><identifier>PMID: 36341493</identifier><language>eng</language><publisher>United States</publisher><subject>Antibodies, Viral ; BNT162 Vaccine ; COVID-19 - prevention & control ; COVID-19 Vaccines ; Humans ; Immunity, Cellular ; Immunoglobulin G ; Neoplasms - therapy ; Prospective Studies ; SARS-CoV-2 ; Vaccination</subject><ispartof>Clinical cancer research, 2023-02, Vol.29 (3), p.635-646</ispartof><rights>2022 American Association for Cancer Research.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-1dd8b2fa6894b999ef0d8e16bd7dac361fda1ad053ddbb7e4a9cf4d779e2e5a3</citedby><cites>FETCH-LOGICAL-c356t-1dd8b2fa6894b999ef0d8e16bd7dac361fda1ad053ddbb7e4a9cf4d779e2e5a3</cites><orcidid>0000-0003-3173-0500 ; 0000-0003-4969-2303 ; 0000-0002-1677-2035 ; 0000-0001-9255-3435 ; 0000-0002-1464-163X ; 0000-0001-8802-7352 ; 0000-0002-2420-0301 ; 0000-0002-9184-7703 ; 0000-0002-2171-7954 ; 0000-0003-4094-8253 ; 0000-0003-3994-4968 ; 0000-0001-7014-8682 ; 0000-0002-1340-4165 ; 0000-0003-3701-5305 ; 0000-0002-1951-6715 ; 0000-0003-1690-8198 ; 0000-0002-1358-6405 ; 0000-0002-4607-5660 ; 0000-0002-5619-1913 ; 0000-0003-3104-6151 ; 0000-0001-7128-1354 ; 0000-0001-9516-8305</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,3343,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36341493$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Debie, Yana</creatorcontrib><creatorcontrib>Van Audenaerde, Jonas R M</creatorcontrib><creatorcontrib>Vandamme, Timon</creatorcontrib><creatorcontrib>Croes, Lieselot</creatorcontrib><creatorcontrib>Teuwen, Laure-Anne</creatorcontrib><creatorcontrib>Verbruggen, Lise</creatorcontrib><creatorcontrib>Vanhoutte, Greetje</creatorcontrib><creatorcontrib>Marcq, Elly</creatorcontrib><creatorcontrib>Verheggen, Lisa</creatorcontrib><creatorcontrib>Le Blon, Debbie</creatorcontrib><creatorcontrib>Peeters, Bart</creatorcontrib><creatorcontrib>Goossens, Maria E</creatorcontrib><creatorcontrib>Pannus, Pieter</creatorcontrib><creatorcontrib>Ariën, Kevin K</creatorcontrib><creatorcontrib>Anguille, Sébastien</creatorcontrib><creatorcontrib>Janssens, Annelies</creatorcontrib><creatorcontrib>Prenen, Hans</creatorcontrib><creatorcontrib>Smits, Evelien L J</creatorcontrib><creatorcontrib>Vulsteke, Christof</creatorcontrib><creatorcontrib>Lion, Eva</creatorcontrib><creatorcontrib>Peeters, Marc</creatorcontrib><creatorcontrib>van Dam, Peter A</creatorcontrib><title>Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Patients with cancer display reduced humoral responses after double-dose COVID-19 vaccination, whereas their cellular response is more comparable with that in healthy individuals. Recent studies demonstrated that a third vaccination dose boosts these immune responses, both in healthy people and patients with cancer. Because of the availability of many different COVID-19 vaccines, many people have been boosted with a different vaccine from the one used for double-dose vaccination. Data on such alternative vaccination schedules are scarce. This prospective study compares a third dose of BNT162b2 after double-dose BNT162b2 (homologous) versus ChAdOx1 (heterologous) vaccination in patients with cancer. A total of 442 subjects (315 patients and 127 healthy) received a third dose of BNT162b2 (230 homologous vs. 212 heterologous). Vaccine-induced adverse events (AE) were captured up to 7 days after vaccination. Humoral immunity was assessed by SARS-CoV-2 anti-S1 IgG antibody levels and SARS-CoV-2 50% neutralization titers (NT50) against Wuhan and BA.1 Omicron strains. Cellular immunity was examined by analyzing CD4+ and CD8+ T-cell responses against SARS-CoV-2-specific S1 and S2 peptides. Local AEs were more common after heterologous boosting. SARS-CoV-2 anti-S1 IgG antibody levels did not differ significantly between homologous and heterologous boosted subjects [GMT 1,755.90 BAU/mL (95% CI, 1,276.95-2,414.48) vs. 1,495.82 BAU/mL (95% CI, 1,131.48-1,977.46)]. However, homologous-boosted subjects show significantly higher NT50 values against BA.1 Omicron. Subjects receiving heterologous boosting demonstrated increased spike-specific CD8+ T cells, including higher IFNγ and TNFα levels. In patients with cancer who received double-dose ChAdOx1, a third heterologous dose of BNT162b2 was able to close the gap in antibody response.</description><subject>Antibodies, Viral</subject><subject>BNT162 Vaccine</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines</subject><subject>Humans</subject><subject>Immunity, Cellular</subject><subject>Immunoglobulin G</subject><subject>Neoplasms - therapy</subject><subject>Prospective Studies</subject><subject>SARS-CoV-2</subject><subject>Vaccination</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkdtO3DAQQK2Kqtz6Ca38yIupL3Euj0sKBQkVtKx4tSbxhHWV2IudFPik_iXZLrRPM5o5MyPNIeSL4KdC6PKb4EXJeKbkaV0vmZRMilJ_IAdC64Ipmeu9OX9n9slhSr84F5ng2Seyr3KViaxSB-TP5TSECD0Fb2mNfT_1EOnVMEwe6RLTJviEicIDOJ9GerdY3rE63DNJoRsx0tXaRUu_h4T07OdK5LKRtAt9H56cf5jrU9Mj-9u-h7Z1HkYXPH1y4_o__xtjmhKt1wt78yyo8_R2xtCPaQfW4FuMx-RjB33Cz2_xiKwuzlf1Jbu--XFVL65Zq3Q-MmFt2cgO8rLKmqqqsOO2RJE3trDQqlx0FgRYrpW1TVNgBlXbZbYoKpSoQR2Rk93aTQyPE6bRDC6182PAY5iSkYVSkkshqxnVO7SNIaWIndlEN0B8MYKbrSSzFWC2AswsyUhptpLmua9vJ6ZmQPtv6t2KegVlfo5B</recordid><startdate>20230201</startdate><enddate>20230201</enddate><creator>Debie, Yana</creator><creator>Van Audenaerde, Jonas R M</creator><creator>Vandamme, Timon</creator><creator>Croes, Lieselot</creator><creator>Teuwen, Laure-Anne</creator><creator>Verbruggen, Lise</creator><creator>Vanhoutte, Greetje</creator><creator>Marcq, Elly</creator><creator>Verheggen, Lisa</creator><creator>Le Blon, Debbie</creator><creator>Peeters, Bart</creator><creator>Goossens, Maria E</creator><creator>Pannus, Pieter</creator><creator>Ariën, Kevin K</creator><creator>Anguille, Sébastien</creator><creator>Janssens, Annelies</creator><creator>Prenen, Hans</creator><creator>Smits, Evelien L J</creator><creator>Vulsteke, Christof</creator><creator>Lion, Eva</creator><creator>Peeters, Marc</creator><creator>van Dam, Peter A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3173-0500</orcidid><orcidid>https://orcid.org/0000-0003-4969-2303</orcidid><orcidid>https://orcid.org/0000-0002-1677-2035</orcidid><orcidid>https://orcid.org/0000-0001-9255-3435</orcidid><orcidid>https://orcid.org/0000-0002-1464-163X</orcidid><orcidid>https://orcid.org/0000-0001-8802-7352</orcidid><orcidid>https://orcid.org/0000-0002-2420-0301</orcidid><orcidid>https://orcid.org/0000-0002-9184-7703</orcidid><orcidid>https://orcid.org/0000-0002-2171-7954</orcidid><orcidid>https://orcid.org/0000-0003-4094-8253</orcidid><orcidid>https://orcid.org/0000-0003-3994-4968</orcidid><orcidid>https://orcid.org/0000-0001-7014-8682</orcidid><orcidid>https://orcid.org/0000-0002-1340-4165</orcidid><orcidid>https://orcid.org/0000-0003-3701-5305</orcidid><orcidid>https://orcid.org/0000-0002-1951-6715</orcidid><orcidid>https://orcid.org/0000-0003-1690-8198</orcidid><orcidid>https://orcid.org/0000-0002-1358-6405</orcidid><orcidid>https://orcid.org/0000-0002-4607-5660</orcidid><orcidid>https://orcid.org/0000-0002-5619-1913</orcidid><orcidid>https://orcid.org/0000-0003-3104-6151</orcidid><orcidid>https://orcid.org/0000-0001-7128-1354</orcidid><orcidid>https://orcid.org/0000-0001-9516-8305</orcidid></search><sort><creationdate>20230201</creationdate><title>Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer</title><author>Debie, Yana ; Van Audenaerde, Jonas R M ; Vandamme, Timon ; Croes, Lieselot ; Teuwen, Laure-Anne ; Verbruggen, Lise ; Vanhoutte, Greetje ; Marcq, Elly ; Verheggen, Lisa ; Le Blon, Debbie ; Peeters, Bart ; Goossens, Maria E ; Pannus, Pieter ; Ariën, Kevin K ; Anguille, Sébastien ; Janssens, Annelies ; Prenen, Hans ; Smits, Evelien L J ; Vulsteke, Christof ; Lion, Eva ; Peeters, Marc ; van Dam, Peter A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-1dd8b2fa6894b999ef0d8e16bd7dac361fda1ad053ddbb7e4a9cf4d779e2e5a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibodies, Viral</topic><topic>BNT162 Vaccine</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines</topic><topic>Humans</topic><topic>Immunity, Cellular</topic><topic>Immunoglobulin G</topic><topic>Neoplasms - therapy</topic><topic>Prospective Studies</topic><topic>SARS-CoV-2</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Debie, Yana</creatorcontrib><creatorcontrib>Van Audenaerde, Jonas R M</creatorcontrib><creatorcontrib>Vandamme, Timon</creatorcontrib><creatorcontrib>Croes, Lieselot</creatorcontrib><creatorcontrib>Teuwen, Laure-Anne</creatorcontrib><creatorcontrib>Verbruggen, Lise</creatorcontrib><creatorcontrib>Vanhoutte, Greetje</creatorcontrib><creatorcontrib>Marcq, Elly</creatorcontrib><creatorcontrib>Verheggen, Lisa</creatorcontrib><creatorcontrib>Le Blon, Debbie</creatorcontrib><creatorcontrib>Peeters, Bart</creatorcontrib><creatorcontrib>Goossens, Maria E</creatorcontrib><creatorcontrib>Pannus, Pieter</creatorcontrib><creatorcontrib>Ariën, Kevin K</creatorcontrib><creatorcontrib>Anguille, Sébastien</creatorcontrib><creatorcontrib>Janssens, Annelies</creatorcontrib><creatorcontrib>Prenen, Hans</creatorcontrib><creatorcontrib>Smits, Evelien L J</creatorcontrib><creatorcontrib>Vulsteke, Christof</creatorcontrib><creatorcontrib>Lion, Eva</creatorcontrib><creatorcontrib>Peeters, Marc</creatorcontrib><creatorcontrib>van Dam, Peter A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Debie, Yana</au><au>Van Audenaerde, Jonas R M</au><au>Vandamme, Timon</au><au>Croes, Lieselot</au><au>Teuwen, Laure-Anne</au><au>Verbruggen, Lise</au><au>Vanhoutte, Greetje</au><au>Marcq, Elly</au><au>Verheggen, Lisa</au><au>Le Blon, Debbie</au><au>Peeters, Bart</au><au>Goossens, Maria E</au><au>Pannus, Pieter</au><au>Ariën, Kevin K</au><au>Anguille, Sébastien</au><au>Janssens, Annelies</au><au>Prenen, Hans</au><au>Smits, Evelien L J</au><au>Vulsteke, Christof</au><au>Lion, Eva</au><au>Peeters, Marc</au><au>van Dam, Peter A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2023-02-01</date><risdate>2023</risdate><volume>29</volume><issue>3</issue><spage>635</spage><epage>646</epage><pages>635-646</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Patients with cancer display reduced humoral responses after double-dose COVID-19 vaccination, whereas their cellular response is more comparable with that in healthy individuals. Recent studies demonstrated that a third vaccination dose boosts these immune responses, both in healthy people and patients with cancer. Because of the availability of many different COVID-19 vaccines, many people have been boosted with a different vaccine from the one used for double-dose vaccination. Data on such alternative vaccination schedules are scarce. This prospective study compares a third dose of BNT162b2 after double-dose BNT162b2 (homologous) versus ChAdOx1 (heterologous) vaccination in patients with cancer. A total of 442 subjects (315 patients and 127 healthy) received a third dose of BNT162b2 (230 homologous vs. 212 heterologous). Vaccine-induced adverse events (AE) were captured up to 7 days after vaccination. Humoral immunity was assessed by SARS-CoV-2 anti-S1 IgG antibody levels and SARS-CoV-2 50% neutralization titers (NT50) against Wuhan and BA.1 Omicron strains. Cellular immunity was examined by analyzing CD4+ and CD8+ T-cell responses against SARS-CoV-2-specific S1 and S2 peptides. Local AEs were more common after heterologous boosting. SARS-CoV-2 anti-S1 IgG antibody levels did not differ significantly between homologous and heterologous boosted subjects [GMT 1,755.90 BAU/mL (95% CI, 1,276.95-2,414.48) vs. 1,495.82 BAU/mL (95% CI, 1,131.48-1,977.46)]. However, homologous-boosted subjects show significantly higher NT50 values against BA.1 Omicron. Subjects receiving heterologous boosting demonstrated increased spike-specific CD8+ T cells, including higher IFNγ and TNFα levels. In patients with cancer who received double-dose ChAdOx1, a third heterologous dose of BNT162b2 was able to close the gap in antibody response.</abstract><cop>United States</cop><pmid>36341493</pmid><doi>10.1158/1078-0432.CCR-22-2185</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-3173-0500</orcidid><orcidid>https://orcid.org/0000-0003-4969-2303</orcidid><orcidid>https://orcid.org/0000-0002-1677-2035</orcidid><orcidid>https://orcid.org/0000-0001-9255-3435</orcidid><orcidid>https://orcid.org/0000-0002-1464-163X</orcidid><orcidid>https://orcid.org/0000-0001-8802-7352</orcidid><orcidid>https://orcid.org/0000-0002-2420-0301</orcidid><orcidid>https://orcid.org/0000-0002-9184-7703</orcidid><orcidid>https://orcid.org/0000-0002-2171-7954</orcidid><orcidid>https://orcid.org/0000-0003-4094-8253</orcidid><orcidid>https://orcid.org/0000-0003-3994-4968</orcidid><orcidid>https://orcid.org/0000-0001-7014-8682</orcidid><orcidid>https://orcid.org/0000-0002-1340-4165</orcidid><orcidid>https://orcid.org/0000-0003-3701-5305</orcidid><orcidid>https://orcid.org/0000-0002-1951-6715</orcidid><orcidid>https://orcid.org/0000-0003-1690-8198</orcidid><orcidid>https://orcid.org/0000-0002-1358-6405</orcidid><orcidid>https://orcid.org/0000-0002-4607-5660</orcidid><orcidid>https://orcid.org/0000-0002-5619-1913</orcidid><orcidid>https://orcid.org/0000-0003-3104-6151</orcidid><orcidid>https://orcid.org/0000-0001-7128-1354</orcidid><orcidid>https://orcid.org/0000-0001-9516-8305</orcidid><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 1078-0432
ispartof	Clinical cancer research, 2023-02, Vol.29 (3), p.635-646
issn	1078-0432 1557-3265
language	eng
recordid	cdi_proquest_miscellaneous_2733202129
source	MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; American Association for Cancer Research; Alma/SFX Local Collection
subjects	Antibodies, Viral BNT162 Vaccine COVID-19 - prevention & control COVID-19 Vaccines Humans Immunity, Cellular Immunoglobulin G Neoplasms - therapy Prospective Studies SARS-CoV-2 Vaccination
title	Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T00%3A08%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Humoral%20and%20Cellular%20Immune%20Responses%20against%20SARS-CoV-2%20after%20Third%20Dose%20BNT162b2%20following%20Double-Dose%20Vaccination%20with%20BNT162b2%20versus%20ChAdOx1%20in%20Patients%20with%20Cancer&rft.jtitle=Clinical%20cancer%20research&rft.au=Debie,%20Yana&rft.date=2023-02-01&rft.volume=29&rft.issue=3&rft.spage=635&rft.epage=646&rft.pages=635-646&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-22-2185&rft_dat=%3Cproquest_cross%3E2733202129%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2733202129&rft_id=info:pmid/36341493&rfr_iscdi=true